Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 28Lymphoma, Large B-Cell, Diffuse 21Lymphoma 16Multiple Myeloma 10Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Lymphoma, B-Cell 7Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Burkitt Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms, Plasma Cell 4Lymphoma, Mantle-Cell 4Immunoblastic Lymphadenopathy 4Recurrence 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Primary Effusion 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Waldenstrom Macroglobulinemia 2Plasmablastic Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, T-Cell 2Hematologic Neoplasms 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

dactolisib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Castrate-resistant Prostate Cancer × Prednisone × Clear all
NCT01717898 2018-03-27

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Castrate-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡